Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 3/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL275165 | 1.00 | KDM4E (0.52) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| Sulfuric Acid SCHEMBL28052558 | 1.00 | KDM4E (0.52) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| Sulfuric Acid SCHEMBL27561650 | 0.97 | KDM4E (0.50) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| SCHEMBL6737394 | 0.88 | KDM4E (0.42) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| SCHEMBL28052556 | 0.86 | KDM4E (0.40) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| Sulfuric Acid SCHEMBL637684 | 0.86 | KDM4E (0.40) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| SCHEMBL64656 | 0.83 | — | — | |
| Sulfuric Acid SCHEMBL5693208 | 0.82 | KDM4E (0.37) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| Sulfuric Acid SCHEMBL28365745 | 0.80 | KDM4E (0.46) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| SCHEMBL6195802 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119643873-A | Method for efficiently enriching N-terminal modified peptide fragments of various proteins | 宁波大学 | 2025-03-18 | — | — | CN | claimed |
| US-20240317750-A1 | An Efficient Process for the Synthesis of Methylliberine and Polymorphs Thereof | FERTIS INDIA PVT LTD (IN) | 2024-09-26 | — | — | US | claimed |
| CN-117597130-A | Efficient process for synthesizing methylliquagmine and polycrystal thereof | 费尔蒂斯印度私人有限公司 | 2024-02-23 | — | — | CN | claimed |
| CN-111362839-B | Preparation method of O-methyl-N-nitroisourea | 浙江微智源能源技术有限公司 | 2022-11-29 | — | — | CN | claimed |
| CN-112387128-B | Polyethylene modified multilayer composite membrane for water treatment and preparation method thereof | 江苏厚生新能源科技有限公司 | 2022-05-17 | — | — | CN | claimed |
| EP-1357952-B1 | METHOD FOR COATING MEDICAL DEVICE SURFACES | MEDTRONIC INC (US) | 2010-09-01 | — | — | EP | claimed |
| US-20060193968-A1 | Method for attachment of biomolecules to medical device surfaces | MEDTRONIC, INC. | 2006-08-31 | — | — | US | claimed |
| US-20060099326-A1 | Method for attachment of biomolecules to medical device surfaces | MEDTRONIC, INC. | 2006-05-11 | — | — | US | claimed |
| US-20040086543-A1 | Method for attachment of biomolecules to medical device surfaces | MEDTRONIC, INC. | 2004-05-06 | — | — | US | claimed |
| EP-1357952-A2 | METHOD FOR COATING MEDICAL DEVICE SURFACES | Medtronic, Inc. (US) | 2003-11-05 | — | — | EP | claimed |
| US-6617142-B2 | Method for attachment of biomolecules to medical device surfaces | MEDTRONIC, INC. | 2003-09-09 | — | — | US | claimed |
| US-20020120333-A1 | Method for coating medical device surfaces | KEOGH JAMES R (US) | 2002-08-29 | — | — | US | claimed |
| WO-2002060505-A2 | METHOD FOR COATING MEDICAL DEVICE SURFACES | MEDTRONIC, INC. (US) | 2002-08-08 | — | — | WO | claimed |
| US-20020001834-A1 | METHOD FOR ATTACHMENT OF BIOMOLECULES TO MEDICAL DEVICE SURFACES | MEDTRONIC, INC. | 2002-01-03 | — | — | US | claimed |
| US-6033719-A | Method for covalent attachment of biomolecules to surfaces of medical devices | MEDTRONIC, INC. (US) | 2000-03-07 | — | — | US | claimed |
| US-5928916-A | Ionic attachment of biomolecules with a guanidino moiety to medical device surfaces | MEDTRONIC, INC. (US) | 1999-07-27 | — | — | US | claimed |
| US-5925552-A | Method for attachment of biomolecules to medical devices surfaces | MEDTRONIC, INC. (US) | 1999-07-20 | — | — | US | claimed |
| US-12630582-B2 | Method for biomaterial purification and kits thereof | Life Technologies Corporation (US) | 2026-05-19 | — | — | US | disclosed |
| US-5925552-A | Method for attachment of biomolecules to medical devices surfaces | MEDTRONIC, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| CN-1127249-A | Guanidine derivatives, process for producing granidine derivatives and cosmetics containing guanidine derivatives | KAO CORP (JP) | 1996-07-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630582-B2 | Method for biomaterial purification and kits thereof | CD68, FIBP, BMP2 | KDM4E 3845/4885BLM 561/4885CYP2D6 4830/4885 |
| US-20240317750-A1 | An Efficient Process for the Synthesis of Methylliberine and Polymorphs Thereof | DNMT1, DNMT3A, MGMT | KDM4E 265/4885BLM 2258/4885CYP2D6 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.